Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905993 | 0.92 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4192800 | 0.78 | AR (0.52) | SLC6A2SLC6A4CYP2D6ARS1PR3 | |
| SCHEMBL4207181 | 0.75 | SLC6A4 (0.49) | SLC6A2SLC6A4CYP2D6ARS1PR3 | |
| SCHEMBL3899451 | 0.75 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL14962112 | 0.75 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL318774 | 0.75 | AR (0.42) | AR | |
| SCHEMBL4751606 | 0.75 | PGR (0.44) | AR | |
| SCHEMBL177449 | 0.74 | AR (0.53) | AR | |
| SCHEMBL23715811 | 0.73 | S1PR3 (0.52) | SLC6A2SLC6A4CYP2D6ARS1PR3 | |
| SCHEMBL4184922 | 0.70 | AR (0.65) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| US-20090170886-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-02 | — | — | US | disclosed |
| EP-1915338-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017754-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170886-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | SLC6A2 2927/4885SLC6A4 957/4885SLC6A3 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.